Can Gilead Win In India Where Novartis Failed?
This article was originally published in PharmAsia News
Gilead is walking the talk. It has now sued the Indian Patent Office in the Delhi High Court, challenging the Indian Patent Office over the decision to deny a patent on the metabolites of its blockbuster hepatitis C drug Sovaldi. But whether it will prevail where others have failed may come down to technical and legal definitions.